Managing RAAS-Inhibitor-Associated Hyperkalemia in Patients with CKD – A Balancing Act

Hyperkalemia is a common electrolyte disorder in patients with CKD that can be exacerbated by renin-angiotensin-aldosterone system (RAAS) inhibitors. While hyperkalemia poses potential risks to patients with CKD, the potentially negative impact of discontinuing RAAS inhibitor therapy on long-term renal and cardiovascular outcomes in CKD patients is unclear.

Guest Author: Michelle A. Fravel, PharmD, BCPS

Music by Good Talk